&w=3840&q=100)
Procter & Gamble Health rallies 10%, hits 4-year high on strong Q1 results
Shares of Procter & Gamble Health hit a four-year high at ₹6,475, as they rallied 10 per cent on the BSE in Friday's intra-day trade in an otherwise weak market after the company reported strong earnings for the quarter ended June 2025 (Q1FY26).
The stock price of the pharmaceutical company was quoting at its lowest level since April 2021. It had hit a record high of ₹7,499.95 on February 11, 2021.
At 02:34 PM; Procter & Gamble Health was trading 7 per cent higher at ₹6,312.10, as compared to 0.40 per cent decline in the BSE Sensex.
Q1 results - Procter & Gamble Health
Procter & Gamble Health delivered a strong performance with sales of ₹333 crore, up 20 per cent against a year ago, owing to broad-based growth in domestic and exports business. Profit after tax (PAT) stood at ₹66 crore, against ₹17 crore a year ago, due to strong sales growth and one-time impact of impairment in the base period.
Commenting on the performance, Milind Thatte, Managing Director, P&G Health India, said, "We are pleased with the continued momentum and strong start to the Financial Year 2025-26. These results are a reflection of our commitment towards addressing the evolving needs of our consumers and healthcare professionals, via superior brand building and go to market initiatives while improving supply chain capabilities'.
The company's strategy, centered on a focused portfolio of quality, trusted, and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution and value), constructive disruption and an agile accountable organization, is delivering balanced and sustainable growth results, Milind Thatte said.
Opportunities, outlook
The healthcare sector in India has undergone a significant transformation, fueled by substantial investments in infrastructural development. Since 2016, the Indian healthcare industry has witnessed a consistent growth trajectory. The consumer healthcare sector shows promising prospects for the future. The company is well-positioned to sustain and strengthen its position in the market.
About Procter & Gamble Health
Procter & Gamble Health Limited is one of India's largest vitamins, minerals, and supplements (VMS) companies manufacturing and marketing VMS products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion.
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur, Ariel, Gillette, Head & Shoulders, Olay, Oral-B, Pampers, Pantene, Tide, Vicks, and Whisper. P&G operates in approximately 70 countries worldwide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
7 minutes ago
- Time of India
US, China and Russia: Navigating the superpower trilemma
Today, Indian foreign policy discourse is mired in an important debate. Two key assumptions govern this debate: that New Delhi's ties with the US arguably constitute its most important relationship in the 21st century, and that any negotiations with Beijing are a signal of weakness. India-US relations are undergoing a tense phase. The tensions have primarily been instigated by US President Donald Trump's decision to impose a 25% tariff on India, and an additional, 'unspecified penalty' for continuing to buy energy resources from Russia. His social media comments have gone so far as to refer to both India and Russia as 'dead economies.' Naturally, this has called into question the time-tested nature of the partnership in the face of the 'China challenge'. With the US-China equation changing, India has to balance ties with both as well as work towards its own national interests Speaking of China, after a long period of severed dialogue, postures on both sides have slightly relaxed, though the road to stability vis-à-vis the border issue, or even China's backing of Pakistan, is long and winding. Nonetheless, communication and negotiation between the two neighbours is underway, and is perhaps a welcome break from the silent-but-violent treatment. Besides the volatility in New Delhi's ties with the two superpowers, there exists a bilateral dynamic between the US and China, which vitally impacts India. An intense back-and-forth of escalating tariffs ensued between the two economic giants earlier this year. Yet, Trump's recent statements seem to suggest that a trade deal with Beijing is in the works. So how does that affect India? So far, India has believed that Trump's continued dissatisfaction with Beijing will be a core aspect of mutual convergence between itself and the US. This definitely was the case under the Joe Biden administration. But if anything is certain about Trump, it is that nothing, indeed, is certain. So, the US and China may not be entering a friendly phase, but they sure are inching toward some semblance of stability. The dynamics of this fateful triangle require that India think in its national interests— sustained economic growth and security of its territory from both external and internal threats. And as PM Modi himself remarked in an interview in 2023, '[The] foremost guiding principle in foreign affairs is our country's national interest.' This begs the question: How should New Delhi balance the nuances of its ties with the US and China and the repercussions of their own thaw, while working to achieve its national interests? One way is not to believe that negotiations with China signal weakness. This anxiety is likely to play up as New Delhi and Beijing negotiate. Most recently, India has eased tourism rules, while China has opened up access for Indians to undertake the Kailash Mansarovar Yatra. To a great degree, India's geographical, economic and military constraints require that communication with Beijing continue for sustainable security to be achieved. This is not to say that India should give up its confident posture, or discontinue investments in de-risking or border security. It is also not a call for it to shed its affinity for the US. But the steps toward a thaw with Beijing — high-level political conversations, ministerial-level dialogues, and working mechanism consultations on the border — are necessary. And at a time when Trump seems to be prepared to meet the 'China challenge' alone, India must figure its own way out to do the same. Second, is to evaluate costs when it comes to fulfilling its energy requirements through purchases from Russia. The affordability of such purchases, and the historic nature of ties with Moscow (especially in defence), make it a vital partner to New Delhi. However, Trump is prioritising reciprocal access to the Indian market over having a vital partner in the Indo-Pacific. And in a world where the US is vastly more powerful than India — or in most aspects, even China — much of what Trump says, goes. So the question is, where is the common ground between India not shedding its friendship with Russia, not risking insurmountable tariffs from the US, and not enabling China's unchecked regional power? The intertwined interests of economic growth and stable security seem orthogonal in this situation. But it is important to face facts. If it wasn't buying oil from Russia, India would still get the tariff slap. If there was great openness in the Indian dairy and agricultural markets, which Trump consistently demands, there would still be an 'unspecified penalty' for trading with Russia. So, the acknowledgement that there is no absolute win-win, is essential. It boils down to assessing what is more harmful — not making any adjustments to the trade numbers with Russia, or the US. It is also important to acknowledge the trade-offs — if there is a significant reduction in the imports of oil and/or defence equipment from Russia, and the US becomes the preferred alternative source of imports, Moscow may become unabashed in its support for China in its disputes with India. If trade with Russia continues as is, India shall face agonistic tariffs under Donald Trump and an overall lack of support in regional geopolitics. It is indeed true that India's tariffs continue to remain high, market openness is low, and domestic innovation and production capability face challenges. Hence, is the first step to addressing the above mentioned dilemma to take difficult steps towards phased openness? Most likely. It may assuage Trump's concerns about the US's trade deficit, without creating many troubles in India-Russia relations. Finally, the worrisome trend of self-reliance across the globe is leaving fewer alternatives for India to replace its dependencies on the US, China, or Russia. Where it gets affordable imports, it faces controversial dilemmas. Where it sees a strong partner, it faces chiding and deriding. So, moving forward, even as the willingness to negotiate diplomatically must continue, India must invest in its own trajectory toward economic and military modernisation. Illustration credit: Illustration by Chad Crowe (USA) Facebook Twitter Linkedin Email Disclaimer Views expressed above are the author's own.
The Hindu
7 minutes ago
- The Hindu
Simpler tests could slash biosimilar costs, widen patient access
Most of the drugs that we consume are called 'small molecule drugs'. Their chemical structure is reasonably simple. Disprin, for instance, has a molecular weight of around 180 daltons. There is another breed of drugs that are very large, complex molecules. For instance, the molecular weight of insulin is around 5,800 daltons and that of the monoclonal antibody remicade, about 150,000 daltons. (One dalton is equal to one-12th the mass of a carbon-12 atom.) Small molecule drugs also tend to have fixed structures that do not change for the duration of their use. In contrast, the complex molecules, which we call biologics, are produced in biological systems and therefore during their production slight variations in the structure may arise. However, these variations may have no impact on the stability of the molecule, its efficacy or its side effects. When a company produces a small molecule drug for the first time, it seeks patent protection for that drug. That is, no competitor may make that drug for several years. It is only when the drug goes 'off patent' that competitors may make it. In the absence of competition, the originator company can price the drug very high. Once there is competition, the competitor companies produce generics, which are copies of the original drug. They don't undertake the research and development to make the drug and they may not spend as much on marketing and sales, so the costs of generics are also much lower. Most of the drugs that you and I take are generics and are priced very cheaply compared to the originator drug. A good example is Sovaldi, a drug used to treat hepatitis C: it originally cost $84,000 for a 12-week course in the US but that dropped to $1,000 once Indian generic firms started making it. Largely it is generic drugs that keep us in India alive and well. Since biologics made by a generic firm will be produced by different biological systems, they may not be identical to those made by the originator company. Thus they are called biosimilars, not generics. For many years, a debate has raged over how much proof is required for a manufacturer to prove that a given biosimilar will work as well as the original biologic drug. Therefore, whereas much simpler testing was required to show that a generic small molecule was working like the originator molecule, there are more elaborate and expensive tests for biosimilars. Major drug regulators such as those of the US, the UK, and in Europe have been working to determine how they can simplify the requirements for approving a biosimilar, in view of the availability of modern analytical techniques. For example, the UK has removed animal trials and the US has planned to replace them with more human-relevant methods (like using organoids). In India, this requirement has not yet been updated although there is a proposal to waive animal studies on a case-by-case basis. Some have also argued that India should follow the practices of the UK and the US. The same holds for the more expensive clinical trials, which in the UK are currently required only in certain cases. Biosimilars need to be made less expensively while ensuring efficacy and minimal adverse effects. The larger the number of affordable biosimilars, the more options we will have for our patients. Gayatri Saberwal is a consultant at the Tata Institute for Genetics and Society.
Time of India
21 minutes ago
- Time of India
Centre picks Medak for pharma energy scheme
1 2 Hyderabad: The Centre has selected Medak district in Telangana to promote global energy efficiency technologies in the pharma industryunder the Assistance in Deploying Energy Efficient Technologies in Industries and Establishments (ADEETIE). Through this scheme, MSMEs are expected to reduce energy consumption by 30 to 50%, enhance their power-to-product ratio, and support the creation of green energy corridors. The Centre has allocated Rs 1,000 crore for the scheme across the country. Being implemented by the Bureau of Energy Efficiency (BEE), the scheme aims to accelerate the adoption of advanced energy-efficient technologies in MSMEs. BEE has called upon all state govts to act swiftly and ensure the successful implementation of ADEETIE, urging engagement with state-designated agencies (SDAs) to inform stakeholders, identify suitable clusters, and assist MSMEs in transitioning to new technologies. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad ADEETIE is being rolled out across 60 industrial clusters and 14 energy-intensive sectors, such as textiles, foundries, and food processing, through a phased and cluster-specific approach targeting precise interventions for tangible outcomes. BEE has selected five states for the ADEETIE scheme to promote global energy efficiency technologies in the pharma industry, including Telangana. Apart from Medak, the scheme will also be implemented in Baddi, Madgaon, Ahmedabad, and Bidar for pharma sector innovation. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Indian NRIs Are Getting Eligible For INR 2 Lakh Monthly Pension On Retirement. Invest 18K/M Get Offer Undo by Taboola by Taboola "ADEETIE is a big boon to the MSME sector," said Akash Tripathi, additional secretary, ministry of power and director general, BEE, urging all states to leverage this opportunity from the outset to ensure the scheme's success and optimise benefits for their industries. From the ₹1,000-crore budget, ₹875 crore is designated as interest subvention to facilitate concessional finance for energy-efficient upgrades, with ₹50 crore earmarked for implementation and capacity-building. The initiative is projected to mobilise investments of over ₹9,000 crore, including substantial contributions from MSMEs themselves. The Union govt views the scheme as an essential tool for post-pandemic recovery and for fostering long-term sustainability, employment generation, and the pursuit of India's climate and net-zero objectives. Get the latest lifestyle updates on Times of India, along with Friendship Day wishes , messages and quotes !
